Imitrex

Treatment with Sumatripan should be done just before the starting of a migraine attack. Recommended oral dose of adults is 25-50 mg, the dose maybe increased up to 100 mg if necessary. The medication is effective at any stage of the attack but if it does not help during the attack additional dose should not be taken. Treatment with Sumatriptan should be continued to prevent the next attack. Tablet of Sumatriptan should be swallowed whole, take it with a big glass of water. Usual intranasal dose of 5-20 mg may be increased to the maximum dose of 40 mg daily.

Sumatriptan is used only to treat an acute, classic migraine attack or a cluster headache, it should not be used for treatment of certain unusual types of migraine. Patients with uncontrolled high blood pressure should not use Sumatriptan.

Hypersensitivity, basal, ophtalmoplegic, hemiplegic forms of migraine, ischemic heart disease (including suspected it), angina (including angina Printsmetala), myocardial infarction (also in history), hypertension, peripheral arterial occlusive disease, stroke or transient cerebrovascular accident (also in history), liver and kidney failure. Cautiousness should be exercised in patients with epilepsy (including any condition with low epileptic threshold), hypertension, pregnancy, breastfeeding, in infants and adolescents (younger than 18 y.o.), in patients older than 65 y.o.; simultaneous intake of medications which contain ergotamine and its derivatives, MAO inhibitors, and also during the period of 14 days after their cancellation.

This medication is usually well tolerated and adverse reactions are not expected. Most frequent side effects include pain or tightness in the chest or throat, tingling, flushing, weakness, dizziness, abdominal discomfort, sweating, nasal irritation, and injection site reactions. Allergic reactions as adverse reactions of organism to Sumatriptan are also possible.

Co-administration with ergotamine and medications containing ergotamin may develop a continued spasm of blood vessels (the interval between administration of these medications must be at least 24 h). Interaction of Sumatriptan and MAO inhibitors (isocarboxazid (Marplan), phenelzine (Nardil), tranylcypromine (Parnate), and procarbazine (Matulane)) is also possible resulting in increased concentration of Sumatriptan. Concomitant use of Sumatriptan with selective serotonin reuptake inhibitors or SSRIs, including fluoxetine (Prozac), citalopram (Celexa), paroxetine (Paxil), and sertraline (Zoloft) or serotonin and norepinephrine reuptake inhibitors, including venlafaxine (Effexor), duloxetine (Cymbalta), and desvenlafaxine (Pristiq) may promote weakness, hyperreflexia and poor coordination of movements.

Sumatriptan is not meant for regular use, it is taken only during an attack.

Be especially attentive to such symptoms as bluish tinge to the skin, convulsions, dilated pupils, inactivity, lack of coordination, paralysis, redness in the arms and legs, skin changes at the site of injection, slow breathing, sluggishness, tremor as they may be signs of Sumatriptan overdose. Inform your health care advisor immediately about your condition nor seek for emergency medical help.

Store this medication at a temperature of 2-30 C (36-86 F) in a tight container resistant to light and moisture.

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.